Assess whether a CMO finding is a delay or a refuse-to-file risk (8e0b2f)

Situation

A boxed-warning proposal from the review division put disproportionate reporting signal workbook in front of pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate. This Pharma & Life Sciences / Pharmacovigilance close is a CMO finding is from disproportionate reporting signal workbook, and the live options are A CMO finding is a delay, A refuse-to-file risk.

Decision

Pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate must choose A CMO finding is a delay / A refuse-to-file risk using disproportionate reporting signal workbook after a boxed-warning proposal from the review division.

Hypotheses to test

• Pharmacovigilance medical reviewer can defend A CMO finding is a delay from disproportionate reporting signal workbook after a boxed-warning proposal from the review division in a Pharma & Life Sciences challenge.
• Pharmacovigilance medical reviewer cannot defend A CMO finding is a delay from disproportionate reporting signal workbook; A refuse-to-file risk is what the extract actually supports after a boxed-warning proposal from the review division.
• A boxed-warning proposal from the review division never reached the population in disproportionate reporting signal workbook — reopen intake, do not close a CMO finding is.
• Two facts in disproportionate reporting signal workbook after a boxed-warning proposal from the review division conflict for pharmacovigilance medical reviewer; hold this Pharmacovigilance file.

Analysis required

• Map FDA-response timing and owner in a labeling team facing a boxed-warning debate.
• Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after a boxed-warning proposal from the review division.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences Pharmacovigilance file, read disproportionate reporting signal workbook against a boxed-warning proposal from the review division and write the one fact that would move a CMO finding is for pharmacovigilance medical reviewer.

Recommendation

Choose A CMO finding is a delay / A refuse-to-file risk on this Pharma & Life Sciences / Pharmacovigilance packet (disproportionate reporting signal workbook after a boxed-warning proposal from the review division). Lead with the Pharma & Life Sciences option disproportionate reporting signal workbook can support after a boxed-warning proposal from the review division, then the two facts that force it, then the Monday action for pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate.